Literature DB >> 17393187

[Subgroups of fibromyalgia].

W Müller1, M Schneider, T Joos, H Y Hsu, T Stratz.   

Abstract

As has been shown by a number of working groups, primary fibromyalgia syndrome does not represent a single clinical entity. It is possible to distinguish between a subgroup with high pain sensitivity and no associated psychiatric condition, a second subgroup characterized by depression and concomitant pain symptoms associated with fibromyalgia syndrome, and a third group with somatoform pain disorder of the fibromyalgia type. Bland inflammatory processes must be considered as the cause in the first group, while depression is the underlying reason for the development of pain in the second group. In the third group, serious previous or still existing psychological problems or also insufficient coping with illness symptoms must be regarded as the reason for pain chronification. Group 1 benefits from a blocking of the 5-HT3 receptors by means of tropisetron, for example. This not only affects pain chronification but also the inflammatory process itself. Group 2 needs antidepressant treatment, whereas the focus should be on psychotherapy is group 3. Groups 1 and 2 will also profit from multimodal physical treatment programs; to a certain extent this applies to group 3 as well. So-called mixed types require a combination of therapeutic measures.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17393187     DOI: 10.1007/s00482-007-0541-8

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  30 in total

1.  The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors.

Authors:  Karla P Zeitz; Nicolas Guy; Annika B Malmberg; Sahera Dirajlal; William J Martin; Linda Sun; Douglas W Bonhaus; Cheryl L Stucky; David Julius; Allan I Basbaum
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

Review 2.  Are antidepressants effective in fibromyalgia?

Authors:  Eric Thomas; Francis Blotman
Journal:  Joint Bone Spine       Date:  2002-12       Impact factor: 4.929

3.  A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.

Authors:  Lesley M Arnold; Amy Rosen; Yili Lu Pritchett; Deborah N D'Souza; David J Goldstein; Smriti Iyengar; Joachim F Wernicke
Journal:  Pain       Date:  2005-11-17       Impact factor: 6.961

Review 4.  The relationship between fibromyalgia and major depressive disorder.

Authors:  J I Hudson; H G Pope
Journal:  Rheum Dis Clin North Am       Date:  1996-05       Impact factor: 2.670

5.  Analysis of pain behavior profiles and functional disability in outpatient physical therapy clinics.

Authors:  H A Hankin; T Spencer; S Kegerreis; T Worrell; J M Rice
Journal:  J Orthop Sports Phys Ther       Date:  2001-02       Impact factor: 4.751

6.  [The influence of depression on the effect of Tropisetron in the therapy of fibromyalgia].

Authors:  T Stratz; B Varga; W Müller
Journal:  Z Rheumatol       Date:  2003-02       Impact factor: 1.372

7.  Operant behavioral treatment of fibromyalgia: a controlled study.

Authors:  Kati Thieme; Erika Gromnica-Ihle; Herta Flor
Journal:  Arthritis Rheum       Date:  2003-06-15

8.  [Pain modification by the 5-HT3 receptor antagonist tropisetron in secondary fibromyalgias].

Authors:  Th Stratz; W Müller
Journal:  Fortschr Med Orig       Date:  2002

9.  Evaluation of changes in occupational performance among patients in a pain management program.

Authors:  Elisabeth Persson; Marcelo Rivano-Fischer; Mona Eklund
Journal:  J Rehabil Med       Date:  2004-03       Impact factor: 2.912

10.  Assessing depression in fibromyalgia patients.

Authors:  C S Burckhardt; C A O'Reilly; A N Wiens; S R Clark; S M Campbell; R M Bennett
Journal:  Arthritis Care Res       Date:  1994-03
View more
  5 in total

1.  [Fibromyalgia syndrome. Rheumatic disease or a mental disorder?].

Authors:  W Häuser
Journal:  Schmerz       Date:  2007-10       Impact factor: 1.107

2.  Multiple somatic symptoms predict impaired health status in functional somatic syndromes.

Authors:  F H Creed; B Tomenson; C Chew-Graham; G J Macfarlane; I Davies; J Jackson; A Littlewood; J McBeth
Journal:  Int J Behav Med       Date:  2013-06

Review 3.  [Influence of depression on fibromyalgia : A systematic review].

Authors:  M Lange; F Petermann
Journal:  Schmerz       Date:  2010-08       Impact factor: 1.107

4.  [Validation of the German version of the Regional Pain Scale for the diagnosis of fibromyalgia syndrome].

Authors:  W Häuser; S Schild; M Kosseva; S Hayo; H von Wilmowski; R Alten; J Langhorst; W Hofmann; J Maus; H Glaesmer
Journal:  Schmerz       Date:  2010-06       Impact factor: 1.107

5.  Fibromyalgia and depression.

Authors:  Richard H Gracely; Marta Ceko; M Catherine Bushnell
Journal:  Pain Res Treat       Date:  2011-11-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.